Updated 5-year data from KEYNOTE-942 showed that intismeran autogene plus pembrolizumab maintained durable recurrence-free and distant metastasis-free survival benefits in patients with high-risk resected...
In a phase 3 randomized controlled trial of adults with active IgG4-related disease, weekly subcutaneous obexelimab significantly prolonged time to first flare requiring rescue therapy vs placebo and...
The FDA approval expands the use of marstacimab-hncq (Hympavzi; Pfizer Inc.) for routine prophylaxis to prevent or reduce bleeding episodes in additional pediatric and inhibitor-positive hemophilia A and B...
A randomized clinical trial evaluating 2 types of 1-page educational resources for low back pain found that fact sheets listing treatment options modestly improved patients’ preparedness for shared...
In a resting-state fMRI study of adults with episodic migraine, chronic migraine, and healthy controls, migraine was associated with reduced brain entropy, with partial entropy restoration during attacks.
...
In a cross-sectional questionnaire study of 106 adults with migraine, vomiting-induced migraine pain relief occurred in 54.9% of patients who vomited during attacks, with some reporting pain relief within...
Improving TDF-FTC uptake among US young men who have sex with men on HIV PrEP could yield substantial 10-year value, while a hypothetical study eliminating adverse event uncertainty would not change the...
Featured faculty at The Revolution & Paradigm Shift in Treatment of Migraine, scheduled for July 16-17, 2026, will highlight evolving approaches to migraine diagnosis, prevention, disease burden, and...
The FDA has approved veligrotug-vvze (Lumvoa) for the treatment of thyroid eye disease regardless of disease activity or duration, based on the pivotal phase 3 THRIVE and THRIVE-2 clinical trials.
